We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Euphoria in Silicon Valley turned to panic this week after a Chinese-based startup called DeepSeek released a new large language model (LLM). It’s very good. And it’s very cheap. Not only did DeepSeek ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The animal-health company updated the label for Librela to include side effects such as seizures and paralysis.

With the proof-of-concept data in hand, Moderna and Merck now plan to start a phase 3 study in melanoma patients, as well as other solid tumour types such as lung and colorectal cancers.

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

The results presented here on S. cerevisiae and the DREAM4 data are proof-of-concept results that IDA can predict the strongest causal effects in potentially large-scale biological systems by ...